Close Menu

A Pretty Nice Pasture

The former president of product development at Genentech, Susan Desmond-Hellmann, will be taking up a chancellor post at the University of California, San Francisco, after the Board of Regents votes on her appointment later this week, reports the WSJ Health Blog. Before joining Genentech, Desmond-Hellman trained at UCSF, then practiced as an oncologist. At Genentech, she oversaw the development of Avastin, Herceptin, and Rituxan.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.

Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.

A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.

In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.